Holen Sie sich die Stockscreener-App
19.20
2.07%
0.39
Handel nachbörslich:
19.20
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
Monte Rosa Therapeutics director sells $180,100 of Glue shares By Investing.com - Investing.com Canada
Monte Rosa Therapeutics director sells $180,100 of Glue shares - Investing.com
Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares - Stock Titan
[144] Monte Rosa Therapeutics, Inc. SEC Filing - Stock Titan
GLUE Technical Analysis | Trend, Signals & Chart Patterns | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
IDEA Pharma recognizes Monte Rosa Therapeutics for advancing MGD drug development - Traders Union
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Biotech Monte Rosa lines up TD Cowen and Jefferies investor talks - Stock Titan
Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Monte Rosa Therapeutics (GLUE) — TCG/Chen Yu report 5.5% holding - Stock Titan
[SCHEDULE 13G/A] Monte Rosa Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
BVF Group (GLUE) entities report up to 5.09M shares, 6.3% total - Stock Titan
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 - Moomoo
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar - Traders Union
Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention - Yahoo Finance
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN
Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37 - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating - Moomoo
Monte Rosa Therapeutics 1Q Research and Development Expenses $44.1M >GLUE - Moomoo
10 Health Care Stocks Whale Activity In Today's Session - Sahm
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Investing News Network
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts - ChartMill
MONTE ROSA THERAPEUTICS ($GLUE) Releases Q1 2026 Earnings - Quiver Quantitative
Monte Rosa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Monte Rosa Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M - marketscreener.com
Monte Rosa Therapeutics 1Q 2026: Revenue $4.21M, EPS $(0.45) — 10-Q Summary - TradingView
Monte Rosa (NASDAQ: GLUE) swings to Q1 loss but extends cash runway into 2029 - Stock Titan
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, Vs. FactSet Est of $11.4M - Moomoo
Biotech Monte Rosa says its $671M cash pile funds operations into 2029 - Stock Titan
Monte Rosa (NASDAQ: GLUE) swings to Q1 2026 loss, builds cash runway into 2029 - Stock Titan
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? By Investing.com - Investing.com Australia
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss? - Investing.com India
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Planned Monte Rosa (GLUE) CEO share sale under Rule 10b5-1 - Stock Titan
GLUE Forecast, Price Target & Analyst Ratings | MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE) - ChartMill
Dunn Edmund, principal accounting officer, sells Monte Rosa (GLUE) shares for $2496 - Investing.com
Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 103.45 Million in Common Stocks - Moomoo
Monte Rosa Therapeutics (GLUE) Form 144: RSU 21,865; Markus Warmuth sales listed - Stock Titan
GLUE SEC FilingsMonte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Monte Rosa Therapeutics (GLUE) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Expands By 18.2% - MarketBeat
Monte Rosa Therapeutics | DEF 14A: Definitive information statements - Moomoo
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):